Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Martin

Showing results (251-260 of 278) with videos related to

Pageof 28
Sort By:
The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2021
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B TrialSibylle Loibl, Frederik Marmé, Miguel Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA TrialFederico Rojo, Clive R Taylor, Carlos Barrios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast CancerSara A Hurvitz, Rachel M Layman, Giuseppe Curigliano, et al.
JAMA|May 12, 2011
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancerChristos Hatzis, Lajos Pusztai, Vicente Valero, et al.
The Lancet. Oncology|December 19, 2012
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trialJohn R Mackey, Miguel Martin, Tadeusz Pienkowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2020
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, et al.
The Lancet. Oncology|February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialArlene Chan, Suzette Delaloge, Frankie A Holmes, et al.
The New England Journal of Medicine|June 3, 2005
Adjuvant docetaxel for node-positive breast cancerMiguel Martin, Tadeusz Pienkowski, John Mackey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31Karen A Gelmon, Frances M Boyle, Bella Kaufman, et al.
Pageof 28

Showing results (251-260 of 278) with videos related to

Sort By:
Pageof 28
The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2021
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B TrialSibylle Loibl, Frederik Marmé, Miguel Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA TrialFederico Rojo, Clive R Taylor, Carlos Barrios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast CancerSara A Hurvitz, Rachel M Layman, Giuseppe Curigliano, et al.
JAMA|May 12, 2011
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancerChristos Hatzis, Lajos Pusztai, Vicente Valero, et al.
The Lancet. Oncology|December 19, 2012
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trialJohn R Mackey, Miguel Martin, Tadeusz Pienkowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2020
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, et al.
The Lancet. Oncology|February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialArlene Chan, Suzette Delaloge, Frankie A Holmes, et al.
The New England Journal of Medicine|June 3, 2005
Adjuvant docetaxel for node-positive breast cancerMiguel Martin, Tadeusz Pienkowski, John Mackey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31Karen A Gelmon, Frances M Boyle, Bella Kaufman, et al.
Pageof 28